[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 20 of about 20
1. Vatne V, Litlekalsoey J, Wentzel-Larsen T, Hostmark J: The in vitro effect of paclitaxel on a LacZ-transfected malignant transitional cell line. Anticancer Res; 2005 May-Jun;25(3B):2097-104
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The in vitro effect of paclitaxel on a LacZ-transfected malignant transitional cell line.
  • As bladder cancer is potentially lethal, the development of effective and tolerable therapeutic options is vital.
  • Our model has several advantages over other in vitro models.
  • The microenvironment in vivo is mimicked, and the important interaction between benign and malignant cells is consequently preserved in vitro.
  • Tumour cell aggregates were cultured with continuous paclitaxel exposure to examine the drug's effect on tumour cell migration in monolayer and spheroidal growth in suspension culture.
  • Paclitaxel treatment inhibited both tumour cell migration and spheroidal growth.
  • Growth of the tumour cells encircling the bladder fragment and cellular infiltration of the bladder stroma were both inhibited by paclitaxel treatment.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / pharmacology. Carcinoma, Transitional Cell / drug therapy. Carcinoma, Transitional Cell / pathology. Lac Operon / genetics. Paclitaxel / pharmacology. Urinary Bladder Neoplasms / drug therapy. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Cell Cycle / drug effects. Cell Cycle / genetics. Cell Growth Processes / drug effects. Cell Growth Processes / genetics. Cell Line, Tumor. Cell Movement / drug effects. Cell Movement / genetics. Coculture Techniques. Flow Cytometry. Humans. Neoplasm Invasiveness. Spheroids, Cellular. Transfection. Urinary Bladder / cytology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16158950.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


2. Jones OM, John SK, Lawrance RJ, Fozard JB: Long-term survival is possible after stenting for malignant ureteric obstruction in colorectal cancer. Ann R Coll Surg Engl; 2007 May;89(4):414-7
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term survival is possible after stenting for malignant ureteric obstruction in colorectal cancer.
  • Urinary tract obstruction is easily relieved by either two stage antegrade stenting or one stage retrograde stenting.
  • However, there is little in the literature about outcomes after this procedure and it is unclear which, if any, patients should be offered this intervention.
  • Four patients received chemotherapy after stenting.
  • CONCLUSIONS: Long-term survival is possible in selected patients with recurrent or irresectable colorectal cancer and malignant ureteric obstruction.
  • This appears to be more likely in those patients in whom other treatments, particularly chemotherapy, are available.
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / mortality. Prospective Studies. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Surg Oncol. 2001 Aug;27(5):482-6 [11504520.001]
  • [Cites] Clin Radiol. 2002 Dec;57(12):1118-21 [12475538.001]
  • [Cites] Clin Radiol. 2005 May;60(5):608-12 [15851050.001]
  • [Cites] Ann R Coll Surg Engl. 2005 Jan;87(1):21-4 [15720902.001]
  • [Cites] Br J Urol. 1995 Jul;76(1):101-7 [7544201.001]
  • (PMID = 17535623.001).
  • [ISSN] 1478-7083
  • [Journal-full-title] Annals of the Royal College of Surgeons of England
  • [ISO-abbreviation] Ann R Coll Surg Engl
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1963567
  •  go-up   go-down


3. Kong CH, Singam P, Hong GE, Cheok LB, Azrif M, Tamil AM, Zainuddin ZM: Clinicopathological features of bladder tumours in a single institution in Malaysia. Asian Pac J Cancer Prev; 2010;11(1):149-52
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The incidence was highest among the Chinese (56.6%), followed by Malays (34.9%), Indians (6%) and other races (2.4%).
  • Of the total, 5.3% were papillary urothelial tumours of low malignant potential, 33.3% pTa, 20% pT1, 10.7% pT2, 12.0% pT3 and 18.7% pT4.
  • There were ten radical cystectomies performed for transitional cell carcinomas; two had neobladder reconstruction whereas the other eight had ileal conduits.
  • All the adenocarcinomas and squamous cell carcinomas were treated by radiotherapy due to the advanced stage of the disease while the myeloid sarcoma received chemotherapy.
  • When compared to other studies, the incidence of muscle invasive and high-grade superficial tumours was greater.
  • [MeSH-major] Adenocarcinoma / secondary. Carcinoma, Squamous Cell / secondary. Carcinoma, Transitional Cell / secondary. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Lymphatic Metastasis. Malaysia. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20593947.001).
  • [ISSN] 2476-762X
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


Advertisement
4. Bellmunt J, Albanell J, Paz-Ares L, Climent MA, González-Larriba JL, Carles J, de la Cruz JJ, Guillem V, Díaz-Rubio E, Cortés-Funes H, Baselga J, Spanish Oncology Genitourinary Group: Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine. Cancer; 2002 Aug 15;95(4):751-7
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Unlike conventional chemotherapy regimens, such as methotrexate, vinblastine, doxorubicin, and cisplatin, there are no data available on key predictive factors for response and survival with these novel agents.
  • The pretreatment characteristics analyzed were age, gender, Eastern Cooperative Oncology Group performance status, histopathology (pure transitional versus other), visceral (liver, lung, or bone) metastasis, number of sites of disease, lactate dehydrogenase, and hemoglobin.
  • RESULTS: The factors that were associated with a worse survival in univariate analysis were performance status > 0, presence of visceral metastasis, and more than one site of malignant disease.
  • Median survival times in the groups of patients with zero, one, or two of these risk factors were 32.8 months, 17 months, and 9.6 months, respectively (P = 0.0005).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Transitional Cell / drug therapy. Carcinoma, Transitional Cell / mortality. Deoxycytidine / analogs & derivatives. Urologic Neoplasms / drug therapy. Urologic Neoplasms / mortality. Urothelium
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Paclitaxel / administration & dosage. Survival Analysis. Urinary Bladder Neoplasms / drug therapy. Urinary Bladder Neoplasms / mortality

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 American Cancer Society.DOI 10.1002/cncr.10762
  • (PMID = 12209718.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


5. Słojewski M: [Results of radical cystectomy for management of invasive bladder cancer with special reference to prognostic factors and quality of life depending on the type of urinary diversion]. Ann Acad Med Stetin; 2000;46:217-29
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Results of radical cystectomy for management of invasive bladder cancer with special reference to prognostic factors and quality of life depending on the type of urinary diversion].
  • Bladder cancer is one of the main problems in urology in terms of diagnosis and treatment, due to its high incidence, high recurrence rate, and difficulties in prognosis of its natural history.
  • According to Polish epidemiological reports, bladder cancer was the fifth cause of death due to malignant diseases in 1993 (1.2% in females and 4.0% in males).
  • Radical cystectomy remained for over forty years the main method of treatment in cases of invasive bladder cancer.
  • Improvements in postoperative care, surgical techniques and methods of urine diversion made cystectomy a widely performed, low mortality procedure.
  • Ileal neobladders were created in 24 cases (25.2%) and in 25 patients (26.3%) other types of urine diversion were used.
  • Median follow-up time was 17.4 months.
  • The tumor was graded G1, G2 and G3 in 3.4%, 22.5%, and 74.1%, respectively.
  • Different forms of adjuvant or neoadjuvant therapy, e.g. radiotherapy, systemic chemotherapy, intra-arterial chemotherapy, electrochemotherapy were used in 28 patients.
  • Patients with Bricker's ileal conduit rated their present health status worse than the other groups.
  • Patients with continent urinary diversion presented the best emotional status and lowest rate of disturbances in self care, professional, social and leisure activities.
  • Radical cystectomy is the best method of treatment in invasive bladder cancer, although it offers a poor chance of curing the patient.
  • In other cases this is just a palliative procedure, thereby justifying the selection of simple methods of urine diversion.
  • [MeSH-major] Carcinoma, Transitional Cell / surgery. Cystectomy / methods. Quality of Life. Urinary Bladder Neoplasms / surgery. Urinary Diversion / methods
  • [MeSH-minor] Chemotherapy, Adjuvant. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Bladder cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11712306.001).
  • [ISSN] 1427-440X
  • [Journal-full-title] Annales Academiae Medicae Stetinensis
  • [ISO-abbreviation] Ann Acad Med Stetin
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


6. Pinthus JH, Sheffer Y, Nagler A, Fridman E, Mor Y, Genina O, Pines M: Inhibition of Wilms tumor xenograft progression by halofuginone is accompanied by activation of WT-1 gene expression. J Urol; 2005 Oct;174(4 Pt 2):1527-31
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibition of Wilms tumor xenograft progression by halofuginone is accompanied by activation of WT-1 gene expression.
  • PURPOSE: Wilms tumor (WT) is the most common malignant neoplasm of the urinary tract in children.
  • Although it is curable with long-term survival, the combination of surgery, chemotherapy and often radiotherapy in some cases results in severe complications in adulthood.
  • Therefore, novel therapeutic strategies that would decrease treatment burden and improve outcome for high risk patients are required.
  • We evaluated the efficacy of halofuginone, an inhibitor of collagen type I synthesis and angiogenesis, to inhibit WT development in xenografts models.
  • Halofuginone was administered intraperitoneally (2 mug per mouse every other day) or given in the diet (1 part per million).
  • RESULTS: Independent of disease stage, tumor location or administration route, halofuginone caused a decrease in angiogenesis that resulted in marked inhibition of tumor development.
  • This result was accompanied by a reduction in collagen synthesis, reduced levels of hepatocyte growth factor receptor MET and increased levels of the tumor suppressor protein WT1.
  • In culture halofuginone increased the synthesis of WT1 in the human WT cell-line SK-NEP-1 and in other cancer cell lines such as hepatocellular carcinoma and prostate cancer.
  • Because of its unique mode of action, halofuginone may decrease the treatment burden when combined with chemotherapy.
  • [MeSH-major] Angiogenesis Inhibitors / pharmacology. Kidney Neoplasms / drug therapy. Quinazolines / pharmacology. WT1 Proteins / biosynthesis. Wilms Tumor / drug therapy

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Wilms Tumor.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16148645.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Piperidines; 0 / Quinazolines; 0 / Quinazolinones; 0 / WT1 Proteins; 9007-34-5 / Collagen; EC 2.7.10.1 / Proto-Oncogene Proteins c-met; EC 2.7.10.1 / Receptor, ErbB-2; L31MM1385E / halofuginone
  •  go-up   go-down


7. Chakravarti A, Winter K, Wu CL, Kaufman D, Hammond E, Parliament M, Tester W, Hagan M, Grignon D, Heney N, Pollack A, Sandler H, Shipley W: Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: a report from the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys; 2005 Jun 1;62(2):309-17
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: a report from the Radiation Therapy Oncology Group.
  • In many tumor types, overexpression of these proteins is associated with enhanced malignant potential.
  • Our objective in this study was to investigate the clinical relevance of EGFR and Her-2 expression in bladder cancer cases from four prospective Radiation Therapy Oncology Group (RTOG) bladder preservation trials using cisplatin-containing chemoradiation (RTOG 8802, 8903, 9506, and 9706).
  • METHODS AND MATERIALS: Tumors from 73 cases from patients with muscle-invading T2-T4a bladder cancers had slides interpretable for EGFR staining; 55 cases had slides interpretable for Her-2 staining.
  • On multivariate analysis adding tumor stage, tumor grade, whether a visibly complete transurethral resection of bladder tumor (TURBT) was done or not, and patient age to the model, EGFR positivity was significantly associated with improved DSS.
  • The other markers examined in this study were not found to have any prognostic value in this setting.
  • Further investigations are warranted into how EGFR family members regulate response to chemoradiation in bladder cancer and their potential therapeutic implications.
  • [MeSH-major] Receptor, Epidermal Growth Factor / metabolism. Receptor, ErbB-2 / metabolism. Urinary Bladder Neoplasms / metabolism
  • [MeSH-minor] Analysis of Variance. Antineoplastic Agents / therapeutic use. Cisplatin / therapeutic use. Combined Modality Therapy. Cyclin-Dependent Kinase Inhibitor p16 / metabolism. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Prognosis. Retinoblastoma Protein / metabolism. Tumor Suppressor Protein p53 / metabolism

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15890569.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U10 CA21661; United States / NCI NIH HHS / CA / U10 CA32115; United States / NCI NIH HHS / CA / U10 CA37422
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Retinoblastoma Protein; 0 / Tumor Suppressor Protein p53; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, ErbB-2; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


8. Lopez-Beltrán A, Luque RJ, Vicioso L, Anglada F, Requena MJ, Quintero A, Montironi R: Lymphoepithelioma-like carcinoma of the urinary bladder: a clinicopathologic study of 13 cases. Virchows Arch; 2001 Jun;438(6):552-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphoepithelioma-like carcinoma of the urinary bladder: a clinicopathologic study of 13 cases.
  • Lymphoepithelioma-like carcinoma (LELCA) of the urinary bladder is a rare variant of bladder cancer characterized by a malignant epithelial component densely infiltrated by lymphoid cells.
  • These neoplasms deserve recognition and attention, chiefly because they may be responsive to chemotherapy.
  • Our data suggest that pure and predominant LELCA of the bladder appear to be morphologically and clinically different from other bladder (undifferentiated and poorly differentiated conventional TCC) carcinomas and should be recognized as separate clinicopathological variants of TCC with heavy lymphocytic reaction relevant in patient management.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Aneuploidy. Carcinoma, Transitional Cell / chemistry. Carcinoma, Transitional Cell / mortality. Carcinoma, Transitional Cell / pathology. Carcinoma, Transitional Cell / surgery. DNA, Neoplasm / analysis. Female. Humans. Image Cytometry. Immunoenzyme Techniques. Keratins / analysis. Male. Middle Aged. Mucin-1 / analysis. Neoplasms, Multiple Primary / chemistry. Neoplasms, Multiple Primary / pathology. Survival Rate

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11469686.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Mucin-1; 68238-35-7 / Keratins
  •  go-up   go-down


9. Paner GP, McKenney JK, Epstein JI, Amin MB: Rhabdomyosarcoma of the urinary bladder in adults: predilection for alveolar morphology with anaplasia and significant morphologic overlap with small cell carcinoma. Am J Surg Pathol; 2008 Jul;32(7):1022-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rhabdomyosarcoma of the urinary bladder in adults: predilection for alveolar morphology with anaplasia and significant morphologic overlap with small cell carcinoma.
  • Rhabdomyosarcoma (RMS) represents the most common malignant soft tissue tumor in children and adolescents with the urinary bladder representing a frequent site.
  • Most of these urinary bladder tumors are embryonal RMS, predominantly the botryoid subtype.
  • RMSs of the urinary bladder in adults are distinctively rare and the subject of only case reports.
  • The degree of morphologic overlap with small cell carcinoma of the bladder, a relatively more common round cell tumor in adults, was striking.
  • No other case had previous history of bladder cancer or concurrent carcinoma in situ or invasive urothelial carcinoma.
  • Two patients received chemotherapy, 2 underwent cystectomy, and 1 had transurethral resection alone.
  • In conclusion, (1) RMS of the urinary bladder in adults more commonly presents as a primitive round blue cell neoplasm that has significant morphologic and immunohistochemical overlap with small cell carcinoma of the bladder. (2) Although RMS in children generally have a botryoid embryonal histology with favorable outcome, bladder RMS in adults frequently demonstrates alveolar or unclassified histology, commonly with anaplasia, and have a uniformly aggressive clinical course.
  • [MeSH-major] Carcinoma, Small Cell / pathology. Rhabdomyosarcoma, Alveolar / pathology. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anaplasia. Biomarkers, Tumor / analysis. Cell Nucleus / pathology. Combined Modality Therapy. Desmin / analysis. Diagnosis, Differential. Fatal Outcome. Female. Humans. Male. Middle Aged. MyoD Protein / analysis. Myogenin / analysis. Synaptophysin / analysis

  • Genetic Alliance. consumer health - Rhabdomyosarcoma alveolar.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18469707.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Desmin; 0 / MyoD Protein; 0 / MyoD1 myogenic differentiation protein; 0 / Myogenin; 0 / Synaptophysin
  •  go-up   go-down


10. Wirth M, Plattner VE, Gabor F: Strategies to improve drug delivery in bladder cancer therapy. Expert Opin Drug Deliv; 2009 Jul;6(7):727-44
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Strategies to improve drug delivery in bladder cancer therapy.
  • Current options for bladder cancer therapy include surgery, immunotherapy, chemotherapy and radiotherapy with a trend towards multimodal treatments.
  • Particularly in the field of bladder cancer chemotherapy, efficacy of treatment might be improved by advanced drug delivery strategies aimed at prolonged residence time within the bladder cavity and increased permeability of the bladder wall during intravesical instillation.
  • Moreover, a deeper understanding of the biology of bladder carcinogenesis and malignant progression stimulated the development of a new generation of anticancer drugs for targeted therapies that might result in increased treatment specificity together with lower toxic potential and higher therapeutic indices.
  • This review discusses the available strategies for 'targeted therapy', focusing on molecular targets, and for 'controlled delivery', comprising all other approaches towards improved drug delivery.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Drug Delivery Systems. Urinary Bladder Neoplasms / drug therapy
  • [MeSH-minor] Animals. Delayed-Action Preparations. Disease Progression. Female. Humans. Male. Neoplasm Recurrence, Local / prevention & control. Sex Factors

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19538035.001).
  • [ISSN] 1744-7593
  • [Journal-full-title] Expert opinion on drug delivery
  • [ISO-abbreviation] Expert Opin Drug Deliv
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Delayed-Action Preparations
  • [Number-of-references] 183
  •  go-up   go-down


11. Ro JY, Shen SS, Lee HI, Hong EK, Lee YH, Cho NH, Jung SJ, Choi YJ, Ayala AG: Plasmacytoid transitional cell carcinoma of urinary bladder: a clinicopathologic study of 9 cases. Am J Surg Pathol; 2008 May;32(5):752-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasmacytoid transitional cell carcinoma of urinary bladder: a clinicopathologic study of 9 cases.
  • In this report, we summarized the clinicopathologic features of 9 cases of plasmacytoid transitional cell carcinoma (TCC) of the urinary bladder, a rare variant of TCC.
  • Cystoscopic findings revealed a dominant solid mass with surrounding multiple papillary lesions in 6 cases and multiple masslike lesions in 3 other cases.
  • Four patients were treated by radical cystectomy with chemotherapy, 2 by radical cystectomy alone, 1 each by chemotherapy or intravesical bacillus Calmette-Guerin infusion alone, and 1 did not receive any further therapy.
  • Microscopically, all tumors contained plasmacytoid cells, which composed 30% to 100% of the entire tumor.
  • The plasmacytoid tumor cells were characterized by eccentrically located nuclei and abundant eosinophilic cytoplasm.
  • The mean follow-up in 8 patients was 24.5 months (range, 5 to 47 mo); the other patient was lost to follow-up.
  • Morphologic recognition and distinction from other plasmacytoid malignant neoplasms is critical for its clinical management and immunohistochemical studies may be required for differential diagnosis.
  • [MeSH-major] Carcinoma, Transitional Cell / pathology. Plasma Cells / pathology. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Carcinoma in Situ / pathology. Cell Nucleus / pathology. Combined Modality Therapy. Cystoscopy. Cytoplasm / pathology. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging. Prognosis. Treatment Outcome

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18379419.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


12. Mayer EK, Beckley I, Winkler MH: Lymphoepithelioma-like carcinoma of the urinary bladder--diagnostic and clinical implications. Nat Clin Pract Urol; 2007 Mar;4(3):167-71
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphoepithelioma-like carcinoma of the urinary bladder--diagnostic and clinical implications.
  • There were no other symptoms.
  • INVESTIGATIONS: Physical examination, ultrasound of the urinary tract, and intravenous urography were all unremarkable.
  • Urine microscopy confirmed more than 5 red blood cells per high-power field, but no malignant cells were seen on cytologic assessment.
  • The tumor was completely resected under general anesthesia.
  • DIAGNOSIS: Histologically, the tumor was described as a G3 pT1 transitional cell carcinoma of the bladder.
  • MANAGEMENT: Following the resection of a solitary recurrence 6 weeks after the initial tumor resection, the patient underwent a standard course of intravesical bacillus Calmette-Guérin therapy.
  • Despite this, another tumor was identified 3 months later.
  • Histologically, this tumor was described as a lymphoepithelioma-like carcinoma, of at least grade G3pT1.
  • The patient underwent radical cystoprostatectomy with ileal conduit formation; no adjuvant systemic chemotherapy was given in light of complete tumor resection.
  • [MeSH-major] Carcinoma, Squamous Cell / diagnosis. Cystectomy / methods. Prostatectomy / methods. Urinary Bladder Neoplasms / diagnosis
  • [MeSH-minor] Cystoscopy. Diagnosis, Differential. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Urography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17347662.001).
  • [ISSN] 1743-4289
  • [Journal-full-title] Nature clinical practice. Urology
  • [ISO-abbreviation] Nat Clin Pract Urol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Chen ZF, Wang F, Qin ZK, Dai YP, Zhou FJ, Han H, Liu ZW, Yu SL, Li YH, Ye YL: [Clinical analysis of 14 cases of urachal carcinoma]. Ai Zheng; 2008 Sep;27(9):966-9
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This study was to summarize our clinical experience in the diagnosis and treatment of urachal carcinoma.
  • Soft-tissue masses between the bladder dome and the abdominal wall were detected by imaging examinations; the wall of the bladder was often invaded.
  • Thirteen patients were found adenocarcinoma, the other one was malignant stromal cell tumor.
  • Seven patients underwent extensive partial excision of the bladder, among which one case developed local recurrence 24 months after operation, while the other six cases were followed up for 14-120 months, with a median follow-up of 42 months without recurrence.
  • Three patients underwent radical bladder resection and urinary diversion, two of which were followed up for 16 months and 84 months respectively without recurrence, while the other one died from surgical complications 3 months after operation.
  • One case underwent partial cystectomy at another hospital developed recurrence 10 months after operation.
  • Three advanced cancer patients received chemotherapy, two of which achieved progression free survival for seven and eight months respectively, while the other one died three months after chemotherapy.
  • Radical removal of the tumor during the first treatment and comprehensive therapies for advanced cancer patients and patients with recurrence or metastasis after operation are critical to improve the treatment efficacy of urachal carcinoma.
  • [MeSH-major] Adenocarcinoma / surgery. Cystectomy / methods. Urachus / pathology. Urinary Bladder Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Retrospective Studies. Survival Rate. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18799037.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


14. Kommoss F, Kommoss S, Eichhorn J, Schmidt D: [Transitional cell carcinoma of the ovary. Morphological and clinical features]. Pathologe; 2007 May;28(3):209-14
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Transitional cell carcinoma of the ovary (TCC-O) is a less common type of malignant surface epithelial-stromal tumor of the ovary, still with uncertain incidence.
  • Histologically, TCC-O resembles urothelial carcinoma of the urinary system, and by definition does not contain a Brenner tumor component.
  • TCC-O may not be a bona fide urothelial neoplasm, however, but rather a lesion of the Müllerian type derived from the ovarian surface epithelium.
  • This notion is supported by the existence of mixed tumors consisting of TCC-O and other histological types of ovarian carcinoma, as well as the observation that TCC-O has a Müllerian type but not a urothelial-like immunohistochemical profile.
  • Besides metastatic urothelial carcinoma of the urinary tract, the other types of ovarian carcinoma, as well as sex cord-stromal tumors such as adult granulosa cell tumors, have to be considered in the differential diagnosis of TCC-O.
  • A recent analysis of a large series of advanced ovarian carcinomas treated by radical surgery and postoperative chemotherapy confirms studies that had suggested that TCC-O has a better prognosis (with current treatment) than that of the other histological types of ovarian carcinoma.
  • [MeSH-minor] Biomarkers, Tumor / analysis. Combined Modality Therapy. Diagnosis, Differential. Female. Humans. Immunohistochemistry

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Obstet Gynecol. 1993 Apr;168(4):1178-85; discussion 1185-7 [8475964.001]
  • [Cites] Int J Gynecol Pathol. 1996 Jul;15(3):257-65 [8811388.001]
  • [Cites] Am J Surg Pathol. 2003 Nov;27(11):1434-41 [14576476.001]
  • [Cites] Mod Pathol. 1998 Jul;11(7):656-64 [9688187.001]
  • [Cites] Int J Gynecol Pathol. 1987;6(1):29-39 [3570630.001]
  • [Cites] Cancer. 1989 Mar 1;63(5):839-47 [2644014.001]
  • [Cites] Am J Clin Pathol. 1998 Feb;109(2):173-80 [9583889.001]
  • [Cites] Gynecol Oncol. 2005 Apr;97(1):195-9 [15790458.001]
  • [Cites] Histopathology. 2000 May;36(5):433-8 [10792484.001]
  • [Cites] Virchows Arch. 2001 Feb;438(2):181-91 [11253121.001]
  • [Cites] Am J Surg Pathol. 2004 Apr;28(4):453-63 [15087664.001]
  • [Cites] Int J Gynecol Pathol. 1988;7(3):197-211 [2846458.001]
  • [Cites] Am J Clin Pathol. 1990 Apr;93(4):457-65 [2321577.001]
  • [Cites] J Natl Cancer Inst. 2003 Sep 3;95(17):1320-9 [12953086.001]
  • [Cites] Hum Pathol. 1996 Dec;27(12):1267-72 [8958296.001]
  • (PMID = 17447068.001).
  • [ISSN] 0172-8113
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


15. Cheng L, Foster SR, MacLennan GT, Lopez-Beltran A, Zhang S, Montironi R: Inflammatory myofibroblastic tumors of the genitourinary tract--single entity or continuum? J Urol; 2008 Oct;180(4):1235-40
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inflammatory myofibroblastic tumors of the genitourinary tract--single entity or continuum?
  • PURPOSE: Inflammatory myofibroblastic tumor of the genitourinary tract is a spindled soft tissue lesion that is often mistaken for sarcoma.
  • The relationship between inflammatory myofibroblastic tumor and other morphologically similar entities has been a long-standing source of controversy.
  • We investigated whether inflammatory myofibroblastic tumors in adults and children are the same entity, and whether inflammatory myofibroblastic tumor is part of a biological spectrum that includes benign and malignant entities at opposite ends.
  • CONCLUSIONS: Inflammatory myofibroblastic tumor of the genitourinary tract should be considered a neoplasm of uncertain malignant potential, and routine surveillance and close clinical followup are recommended.
  • Aggressive therapy (radical cystectomy, radiation or chemotherapy) is unwarranted given the indolent and often benign clinical course for the majority of cases.
  • To understand the diagnostic and prognostic implications future emphasis should be placed on the link between genetic abnormalities, and clinical course, therapeutic response and ultimate outcome.
  • [MeSH-minor] Biopsy, Needle. Diagnosis, Differential. Humans. Immunohistochemistry. Incidence. Neoplasm Staging. Prognosis. Risk Assessment. Ureteral Neoplasms / diagnosis. Ureteral Neoplasms / pathology. Urethral Neoplasms / diagnosis. Urethral Neoplasms / pathology. Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18707729.001).
  • [ISSN] 1527-3792
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 40
  •  go-up   go-down


16. Várady E, Deák B, Molnár ZS, Rosta A, Schneider T, Esik O, Eckhardt S: Second malignancies after treatment for Hodgkin's disease. Leuk Lymphoma; 2001 Nov-Dec;42(6):1275-81
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Second malignancies after treatment for Hodgkin's disease.
  • The occurrence of treatment-related second malignancy following Hodgkin's disease (HD) has now been recognized as a major problem.
  • Second neoplasm developed in 32 cases (4.8%).
  • Five patients received chemo- and radiotherapy and in two cases chemotherapy was used.
  • Twenty-five patients have had solid tumors, affecting lung (5), breast (3), colon (3), stomach (2), urinary bladder (2), head-and-neck (1), thyroid gland (1), esophagus (1), liver (1), pancreas (1), furthermore, three sarcomas and two malignant melanomas were observed.
  • Chemotherapy was applied to nine patients, 16 patients received both chemo- and radiotherapy.
  • Since alkylating agents increase the risk of leukemia and irradiation contributes mainly to other malignancies, future treatment protocols should attempt to reduce the most serious consequence of therapy without compromising the survival.
  • [MeSH-major] Hodgkin Disease / therapy. Neoplasms, Second Primary / epidemiology
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / adverse effects. Female. Humans. Male. Middle Aged. Radiotherapy / adverse effects. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11911408.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


17. Buchner AM, Sonnenberg A: Medical diagnoses and procedures associated with clostridium difficile colitis. Am J Gastroenterol; 2001 Mar;96(3):766-72
Genetic Alliance. consumer health - Clostridium Difficile.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: The aim of this study was to examine the associations of Clostridium difficile colitis with other comorbid conditions and procedural interventions among hospitalized patients.
  • METHODS: The Patient Treatment File of the Department of Veterans Affairs contains the computerized records of all inpatients treated in 172 Veterans Affairs hospitals distributed throughout the United States.
  • In a multivariable logistic regression, the occurrence of C. difficile colitis served as outcome variable, whereas the occurrences of other diagnoses or procedures served as predictor variables.
  • The numbers of procedures were 75,479 and 129,612, respectively. C. difficile colitis was significantly associated with HIV infection, candidiasis, malignant neoplasm and chemotherapy, malnutrition, pneumonia, aspiration pneumonitis, intestinal obstruction, diverticulitis, renal failure, urinary tract infection, decubitus, and osteomyelitis.
  • Interventional procedures involving the respiratory tract, bone marrow biopsy, arterial and venous catheterization, urinary catheterization, dialysis, gastrostomy tube, and physical therapy were also frequently associated with the development of C. difficile colitis.
  • CONCLUSIONS: These associations reflect the influence of causal relationships (such as the use of antibiotics and chemotherapy), an increased risk of exposure to C. difficile among immobilized bedridden patients with chronic disease states, or a general system failure in patients with end-stage disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11280548.001).
  • [ISSN] 0002-9270
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Kramer MW, Krege S, Peters I, Merseburger AS, Kuczyk MA: [Targeted therapy of urological tumours. Experimental field or established therapeutic approach?]. Urologe A; 2010 Oct;49(10):1260-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Targeted therapy of urological tumours. Experimental field or established therapeutic approach?].
  • [Transliterated title] Die Target-Therapie urologischer Tumoren. Experimentierfeld oder etablierter therapeutischer Ansatz?
  • Unlike conventional systemic chemotherapies, the aim of targeted therapeutic approaches is not to address general mechanisms involved in cellular replication.
  • In contrast, they aim at such regulatory pathways that have been identified to be involved in the progression of human malignant disease.
  • Whereas the application of targeted therapeutic modalities is well established for the treatment of metastatic renal cell cancer, only very few data on their clinical efficacy during the treatment of other urological tumours such as prostate and bladder cancer are currently available.
  • The aim of this paper is to reflect on the current status regarding the relevance of targeted therapeutic approaches during the treatment of urological cancers of different origin.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Drug Delivery Systems. Drugs, Investigational / administration & dosage. Urologic Neoplasms / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Renal Cell / drug therapy. Carcinoma, Renal Cell / mortality. Carcinoma, Transitional Cell / drug therapy. Carcinoma, Transitional Cell / mortality. Disease Progression. Drug Resistance, Neoplasm. Female. Humans. Kidney Neoplasms / drug therapy. Kidney Neoplasms / mortality. Male. Prognosis. Prostatic Neoplasms / drug therapy. Prostatic Neoplasms / mortality. Protein-Tyrosine Kinases / antagonists & inhibitors. Randomized Controlled Trials as Topic. Receptors, Vascular Endothelial Growth Factor / antagonists & inhibitors. TOR Serine-Threonine Kinases / antagonists & inhibitors. Testicular Neoplasms / drug therapy. Testicular Neoplasms / mortality. Urinary Bladder Neoplasms / drug therapy. Urinary Bladder Neoplasms / mortality

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8724-9 [16314632.001]
  • [Cites] BJU Int. 2009 Jun;103(12):1636-40 [19154507.001]
  • [Cites] Clin Cancer Res. 2008 Jan 1;14(1):209-14 [18172272.001]
  • [Cites] N Engl J Med. 2007 Jan 11;356(2):115-24 [17215529.001]
  • [Cites] Am J Pathol. 2004 Jan;164(1):305-13 [14695343.001]
  • [Cites] Am J Clin Oncol. 2006 Feb;29(1):12-3 [16462496.001]
  • [Cites] Mol Cancer. 2007 Jul 16;6:49 [17634119.001]
  • [Cites] Ann Oncol. 1999 Nov;10(11):1393-4 [10631474.001]
  • [Cites] Am J Clin Pathol. 1994 Feb;101(2):166-76 [7906919.001]
  • [Cites] N Engl J Med. 2007 Jan 11;356(2):125-34 [17215530.001]
  • [Cites] J Clin Oncol. 2012 May 1;30(13):1534-40 [22454414.001]
  • [Cites] Eur Urol. 2005 Sep;48(3):400-7 [15964136.001]
  • [Cites] Cancer. 2010 Sep 15;116(18):4256-65 [20549832.001]
  • [Cites] Anticancer Res. 1997 Mar-Apr;17(2B):1293-6 [9137488.001]
  • [Cites] Ann Oncol. 2002 Apr;13(4):599-605 [12056711.001]
  • [Cites] J Clin Oncol. 2010 Apr 10;28(11):1850-5 [20231682.001]
  • [Cites] Eur Urol. 2006 Apr;49(4):633-43 [16481093.001]
  • [Cites] Klin Padiatr. 2009 May-Jun;221(3):136-40 [19437360.001]
  • [Cites] Ann Oncol. 2009 May;20(5):913-20 [19403935.001]
  • [Cites] J Clin Oncol. 2010 Feb 1;28(4):537-42 [20026807.001]
  • [Cites] N Engl J Med. 2007 May 31;356(22):2271-81 [17538086.001]
  • [Cites] Clin Cancer Res. 2001 Aug;7(8):2440-7 [11489824.001]
  • [Cites] J Clin Oncol. 2009 Mar 10;27(8):1280-9 [19171708.001]
  • [Cites] Lancet. 2007 Dec 22;370(9605):2103-11 [18156031.001]
  • [Cites] Urol Oncol. 2004 Jan-Feb;22(1):1-6 [14969795.001]
  • [Cites] Clin Cancer Res. 2009 Feb 15;15(4):1411-6 [19228742.001]
  • [Cites] J Clin Oncol. 2000 Sep;18(17):3068-77 [11001674.001]
  • [Cites] J Clin Oncol. 2010 Feb 20;28(6):1061-8 [20100962.001]
  • [Cites] Science. 1985 Sep 6;229(4717):974-6 [2992089.001]
  • [Cites] J Clin Oncol. 2002 Nov 15;20(22):4448-52 [12431967.001]
  • [Cites] N Engl J Med. 2007 Jul 26;357(4):340-8 [17652649.001]
  • [Cites] BJU Int. 2008 Apr;101(7):795-803 [18070193.001]
  • [Cites] Oncol Rep. 2001 Jan-Feb;8(1):9-15 [11115562.001]
  • [Cites] J Clin Oncol. 2009 Aug 1;27(22):3584-90 [19487381.001]
  • [Cites] Mod Pathol. 2009 Jan;22(1):7-12 [18660793.001]
  • (PMID = 20848076.001).
  • [ISSN] 1433-0563
  • [Journal-full-title] Der Urologe. Ausg. A
  • [ISO-abbreviation] Urologe A
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antineoplastic Agents; 0 / Drugs, Investigational; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptors, Vascular Endothelial Growth Factor
  •  go-up   go-down


19. Yoshida S, Nakagomi K, Goto S, Futatsubashi M, Torizuka T: 11C-choline positron emission tomography in prostate cancer: primary staging and recurrent site staging. Urol Int; 2005;74(3):214-20
Hazardous Substances Data Bank. CHOLINE CHLORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 11C-choline positron emission tomography in prostate cancer: primary staging and recurrent site staging.
  • OBJECTIVES: To evaluate the usefulness of 11C-choline positron emission tomography (PET) for primary staging and re-staging of prostate cancer.
  • PATIENTS AND METHODS: 11C-choline PET, a total of 22 scans, was performed on 13 patients with histologically proven prostate cancer in primary staging (n = 6) and recurrent site staging; following radical prostatectomy (n = 5) and following radiation therapy (n = 3).
  • Also, 3 patients histologically proven to have no malignant prostate were included.
  • RESULTS: Because urinary 11C-choline activity was low, it did not interfere with the visualization of pelvic structures.
  • On the other hand, 11C-choline PET may be of value in recurrent site staging and monitoring for the prostate cancer.
  • [MeSH-major] Carbon Radioisotopes. Choline. Neoplasm Recurrence, Local / radionuclide imaging. Neoplasm Staging / methods. Prostatic Neoplasms / radionuclide imaging
  • [MeSH-minor] Aged. Aged, 80 and over. Drug Combinations. Feasibility Studies. Humans. Injections, Intravenous. Male. Middle Aged. Positron-Emission Tomography. Reproducibility of Results

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 S. Karger AG, Basel.
  • (PMID = 15812206.001).
  • [ISSN] 0042-1138
  • [Journal-full-title] Urologia internationalis
  • [ISO-abbreviation] Urol. Int.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Carbon Radioisotopes; 0 / Drug Combinations; N91BDP6H0X / Choline
  •  go-up   go-down


20. Gaisa NT, Henkel C, Knüchel R: Tumour node metastasis staging of bladder cancer: prognosis versus pitfalls. Curr Opin Urol; 2010 Sep;20(5):398-403
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RECENT FINDINGS: Solid histological diagnosis includes sufficient clinical information and adequate tissue processing.
  • This combined with molecular data will lead to a more clear-cut distinction between benign and malignant and possibly to another change in terminology with higher concordance to other epithelial tumours.
  • We are optimistic that an even more clear-cut distinction between benign recurring, nonprogressing tumours and more aggressive tumours will enable us to focus and limit chemotherapy.
  • [MeSH-major] Lymph Nodes / pathology. Neoplasm Staging. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Humans. Lymphatic Metastasis. Molecular Diagnostic Techniques. Neoplasm Invasiveness. Predictive Value of Tests. Prognosis. Reproducibility of Results

  • Genetic Alliance. consumer health - Bladder cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20625299.001).
  • [ISSN] 1473-6586
  • [Journal-full-title] Current opinion in urology
  • [ISO-abbreviation] Curr Opin Urol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down






Advertisement